Australian Primary Hemp (ASX:APH) - Co founder & CEO, Charles Mann (left), Co founder & Chief Operating Officer, James Hood (right)
Co founder & CEO, Charles Mann (left), Co founder & Chief Operating Officer, James Hood (right)
Sourced: The Weekly Times
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Australian Primary Hemp (APH) Co-founder and CEO Charles Mann has resigned to pursue other opportunities
  • Taking his place, is Neale Joseph who started just a few months ago as the Head of Product
  • Neale has vast leadership experience, having successfully led businesses across several countries
  • APH is down 5.56 per cent on the market this afternoon, trading at 8.5¢ apiece

Australian Primary Hemp’s (APH) co-founder and CEO, Charles Mann, has resigned to pursue other opportunities.

He has also resigned his seat on the board, effective immediately however Charles will be assisting with the handover during his notice period.

APH’s other founder, James Hood, will remain on the board and as Chief Operating Officer. The company says James is fully committed to the business.

The company has already transitioned Head of Product, Neale Joseph, as new CEO with an immediate start.

Neale joined the company just a few months ago but is an experienced CEO. He has successfully led businesses across Australia, New Zealand, the Asia Pacific and the Middle East.

He recently co-founded a successful start-up in the natural health and beauty industry.

Neale previously worked with companies such as Pure Beauty Australia and David Jones.

“APH is delighted to appoint Neale Joseph as CEO, having already made a large impact to the organisation during his short time at APH,” Chairman Cameron Petricevic said.

“Neale has both impressive experience and a proven track record that are perfectly suited to APH’s current stage of development and potential. With his appointment, APH is well-positioned to accelerate growth,” he added.

APH is down 5.56 per cent on the market this afternoon, trading at 8.5¢ apiece at 1:10pm AEDT.

aph by the numbers
More From The Market Online
The Market Online Video

Syntara shows encouraging first signals it can impact the path to Parkinson’s

Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence
Diabetes concept

Entropy reports 50% remission in Phase 2 psychedelic trial for binge eating disorder

Entropy Neurodynamics says its Phase 2 trial of TRP-8803 delivered 50% remission in all treatment-resistant binge…

Syntara reports encouraging early Parkinson’s trial results

Syntara has reported statistically significant reductions in brain inflammation in an early-stage Parkinson's disease study.

OncoSil Medical files for US FDA approval for specialist device

OncoSil Medical has hit a key milestone in its plans to commercialise its unique OncoSil device…